HC Wainwright & Co. Downgrades Pacira BioSciences to Neutral, Lowers Price Target to $36.5

Benzinga Newsdesk www.benzinga.com Negative 92.7%

Neg 92.7% Neu 0% Pos 0%

HC Wainwright & Co. analyst Douglas Tsao downgrades Pacira BioSciences (NASDAQ:PCRX) from Buy to Neutral and lowers the price target from $38 to $36.5.